Emerging therapies in bone metastasis.
Skeletal lesions contribute substantially to morbidity and mortality in patients with cancer. Emerging treatments for metastatic bone disease have arisen from our understanding of the biology of bone metastases. Tumour cells alter the functions of bone-resorbing (osteoclasts) and bone-forming (osteoblasts) cells, promoting skeletal destruction. Drugs that inhibit osteoclast-mediated bone resorption (denosumab, bisphosphonates) are the standard of care for patients with skeletal metastases. In this review, we describe the progress and future directions of novel bone-targeted therapies that not only focus on osteoclasts, but also on osteoblasts and the bone microenvironment.
INSERM, UMR 1033, Lyon F-69372, France; Université Lyon-1, Villeurbanne F-69622, France.
Lise
L
Clément-Demange
INSERM, UMR 1033, Lyon F-69372, France; Université Lyon-1, Villeurbanne F-69622, France. Electronic address: philippe.clezardin@inserm.fr.
Philippe
P
Clézardin
D000818:Animals; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D001862:Bone Resorption / Q000188:drug therapy; D015195:Drug Design; D006801:Humans; D058990:Molecular Targeted Therapy; D010006:Osteoblasts / Q000378:metabolism; D010010:Osteoclasts / Q000378:metabolism; D059016:Tumor Microenvironment
D050071:Bone Density Conservation Agents